Optimal Adjuvant Therapy Selection for Chinese BRAF V600‐Mutant Stage III Melanoma: A Multicenter Efficacy Comparison of Targeted Agents, Immunotherapy, and Combinatorial Strategies
= 0.026). NOTCH4 and IL7R mutations may serve as prognostic and predictive biomarkers for long-term survival and targeted-immunotherapy efficacy, respectively. Adjuvant therapy with D/T may represent the most effective treatment strategy for Chinese patients with stage III melanoma harboring BRAF V600 mutations. A combination of BRAF-targeted therapy and aPD-1 immunotherapy provided comparable efficacy and may be an alternative for a specific patient.
Authors
- Qiuyue Ding (ORCID: https://orcid.org/0000-0002-6878-6455)
- Linbin Chen (ORCID: https://orcid.org/0000-0002-9904-7460)
- R Li
- Qianqi Chen
- Ziluan Chen
- J S Li
- Rongcheng Zhang
- Da Li (ORCID: https://orcid.org/0000-0003-2968-3813)
- Xi Zhang (ORCID: https://orcid.org/0000-0002-4638-3997)
- Xizhi Wen
- Baiwei Zhao (ORCID: https://orcid.org/0009-0004-2125-8657)
- Junwan Wu
- Ke Li
- Wei Zheng
- Ya Ding
- Qiming Zhou
- Qiong Zhang
- Yao Liang
Institutions
- Sun Yat-sen University (CN)
- Kunming Medical University (CN)
- ShenZhen People’s Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- MedComm
- Published
- 2026-04-25
- DOI
- https://doi.org/10.1002/mco2.70738
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China
- Wu Jieping Medical Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province